In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2.
Dora BuzasAdrian H BunzelOskar StauferEmily J MilodowskiGrace L EdmundsJoshua C BuftonBeatriz V Vidana MateoSathish K N YadavKapil GuptaCharlotte FletcherMaia K WilliamsonAlexandra HarrisonUfuk BorucuJulien CapinOre FrancisGeorgia BalchinSophie HallMirella V VegaFabien DurbessonSrikanth LingappaRenaud VincentelliJoe RoeLinda WooldridgeRachel BurtRoss J L AndersonAdrian J Mulhollandnull Bristol Uncover GroupJonathan HareMick BaileyAndrew D DavidsonAdam FinnDavid MorganJamie MannJoachim SpatzFrederic GarzoniChristiane SchaffitzelImre BergerPublished in: Antibody therapeutics (2023)
Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.